A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial

Vaccine

Volumn 33, Issue 21, 2015, Pages 2500-2510

  Block, Stan L ^a   Szenborn, Leszek ^b   Daly, Wendy ^c   Jackowska, Teresa ^d   D'Agostino, Diego ^e   Han, Linda ^f   Dull, Peter M ^f   Smolenov, Igor ^e  

^a Kentucky Pediatric Research Institute   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c HealthSouth Surgicenter of Louisville   (United States)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^e Research and Development   (Netherlands)

^f Novartis Vaccines and Diagnostics Inc ^*  (United States)

Author keywords

Adolescent; Conjugate vaccines; Immunogenicity; Meningococcal; NCT01272180; Safety

Indexed keywords

MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PLACEBO; RECOMBINANT PROTEIN; BACTERIUM ANTIBODY; VACCINE;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; CHILL; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE PAIN; LOSS OF APPETITE; LYMPHADENOPATHY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; STREPTOCOCCAL PHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VACCINATION REACTION; BLOOD; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PATHOLOGY; PROCEDURES; SERUM BACTERICIDAL ACTIVITY; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PLACEBOS; SEROGROUP; SINGLE-BLIND METHOD; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84928591299     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.001     Document Type: Article

References (45)

1. Pace D., Pollard A.J. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012, 30(SUPPL. 2):B3-B9.
2. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(SUPPL. 2):B51-B63.
3. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
4. MacLennan J., Kafatos G., Neal K., Andrews N., Cameron J.C., Roberts R., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12:950-957.
5. World Health Organization (WHO) Meningococcal disease control in countries of the African meningitis belt, 2013. Wkly Epidemiol Rec 2014, 89:205-220.
6. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30(SUPPL. 2):B26-B36.
7. Trotter C.L., Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007, 31:101-107.
8. Daugla D., Gami J., Gamougam K., Naibei N., Mbainadji L., Narbe M., et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2013, 383:40-47.
9. Novak R.T., Kambou J.L., Diomadé F.V., Tarbangdo T.F., Ouédraogo-Traoré R., Sangaré L., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764.
10. Keyserling H., Pollard A.J., DeTora L.M., Gilmet G.P. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines 2006, 5:445-459.
11. Broker M., Cooper B., Detora L.M., Stoddard J.J. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist 2011, 4:137-147.
12. Croxtall J.D., Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix). Drugs 2012, 72:2407-2430.
13. Klein N.P., Reisinger K.S., Johnston W., Odrljin T., Gill C.J., Bedell L., et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012, 31:64-71.
14. Black S., Klein N.P., Shah J., Bedell L., Karsten A., Dull P.M. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010, 28:657-663.
15. Jackson L.A., Baxter R., Reisinger K., Karsten A., Shah J., Bedell L., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49:e1-e10.
16. Reisinger K.S., Baxter R., Block S.L., Shah J., Bedell L., Dull P.M. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009, 16:1810-1815.
17. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299:173-184.
18. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972, 126:514-521.
19. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
20. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
21. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103:10834-10839.
22. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13:416-425.
23. Frosi G., Biolchi A., Lo Sapio M., Rigat F., Glichrist S., Lucidarme J., et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CmenB vaccine strain coverage. Vaccine 2013, 31:4968-4974.
24. Nissen M., Tozer S., Whiley D., Smith H., Rockett R., Jennison A., et al. Use of the meningococcal antigen typing system (MATS) to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine. Presented at the 19th International Pathogenic Neisseria Conference (IPNC) 2012,269. http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf.
25. Kim E., Paulos S., Carlone G., Plikaytis B., Cohn A., Messonnier N., et al. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. Presented at the 19th International Pathogenic Neisseria Conference (IPNC) 2012,270. http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf.
26. Lemos A.P., Gorla M.C., Brandileone M.C., Orlandi L., Rigat F., Boccadifuoco G., et al. MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains. Presented at the 19th International Pathogenic Neisseria Conference (IPNC) 2012,272. http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf.
27. Bettinger J.A., Scheifele D.W., Halperin S.A., Le Saux N., Vaudry W., Findlow J., et al. Estimated coverage of Canadian meningococcal B isolates by a meningococcal serogroup B vaccine. 5th Vaccine & International Society for Vaccines Annual Global Congress 2011, Poster P1.2.4.
28. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29:e71-e79.
29. Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7:646-653.
30. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
31. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
32. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
33. Centers for Diseases Control and Prevention Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013, 62:1-28.
34. Mandal S., Wu H.M., MacNeil J.R., Machesky K., Garcia J., Plikaytis B.D., et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis 2013, 57:344-348.
35. Centers for Disease Control and Prevention Princeton University meningococcal disease outbreak 2014, Centers for Disease Control and Prevention, http://www.cdc.gov/meningococcal/outbreaks/princeton.html.
36. Centers for Disease Control and Prevention University of California, Santa Barbara meningococcal disease outbreak 2014, Centers for Disease Control and Prevention, http://www.cdc.gov/meningococcal/outbreaks/ucsb.html.
37. Mak P.A., Santos G.F., Masterman K.A., Janes J., Wacknov B., Vienken K., et al. Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol 2011, 18:1252-1260.
38. Derringer G., Suich R. Simultaneous optimization of several response variables. J Qual Technol 1980, 12:214-219.
39. Gasparini R., Amicizia D., Domnich A., Lai P.L., Panatto D. Neisseria meningitidis B vaccines: recent advances and possible immunization policies. Expert Rev Vaccines 2014, 13:345-364.
40. Ball L.K., Falk L.A., Horne D., Finn T.M. Evaluating the immune response to combination vaccines. Clin Infect Dis 2001, 33:S299-S305.
41. Beernink P.T., Caugant D.A., Welsch J.A., Koeberling O., Granoff D.M. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009, 199:1360-1368.
42. Hong E., Giuliani M.M., Deghmane A.E., Comanducci M., Brunelli B., Dull P., et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa. Vaccine 2013, 31:1113-1116.
43. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107:19490-19495.
44. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(SUPPL. 2):B3-B12.
45. Esposito S., Prymula R., Zuccotti G.V., Xie F., Barone M., Dull P.M., et al. A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother 2014, 10:2005-2014.